Sprouty2 loss‐induced IL6 drives castration‐resistant prostate cancer through scavenger receptor B1

Metastatic castration‐resistant prostate cancer (mCRPC) is a lethal form of treatment‐resistant prostate cancer and poses significant therapeutic challenges. Deregulated receptor tyrosine kinase (RTK) signalling mediated by loss of tumour suppressor Sprouty2 (SPRY2) is associated with treatment resi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:EMBO Mol Med
Autori principali: Patel, Rachana, Fleming, Janis, Mui, Ernest, Loveridge, Carolyn, Repiscak, Peter, Blomme, Arnaud, Harle, Victoria, Salji, Mark, Ahmad, Imran, Teo, Katy, Hamdy, Freddie C, Hedley, Ann, van den Broek, Niels, Mackay, Gillian, Edwards, Joanne, Sansom, Owen J, Leung, Hing Y
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2018
Soggetti:
Research Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5887544/
https://ncbi.nlm.nih.gov/pubmed/29540470
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201708347
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi